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The purpose of this study was to determine whether the use of a periarticular injection using liposomal
bupivacaine could decrease pain and improve outcomes after total knee arthroplasty. Fifty consecutive
patients received no periarticular injections (group A). Another 50 consecutive patients received a per-
iarticular injection of liposomal bupivacaine (group B). There were no differences in the groups with
respect to gender, age, body mass index (BMI), or comorbidities. There was a signiﬁcant reduction in the
amount of narcotics used in the liposomal bupivacaine group (60.97-mg oral morphine equivalent vs
89.74 mg, P ¼ 0.009). Patients in group B with a BMI <40 and a Charlson comorbidity index of 0-3 had
decreased length of stay (2.64 vs 3.06 days, P ¼ .004), narcotic use over 24-48 hours (110.66 vs 182.47 mg,
P ¼ .013), and narcotic use over 48-72 hours (49.61 vs. 112.65 mg, P ¼ .004). In patients with a BMI <40
and comorbidity index of 3, periarticular injection using liposomal bupivacaine leads to earlier
discharge along with decreased use of narcotics.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The number of patients undergoing total knee arthroplasty
(TKA) has increased substantially in the last two decades, and
currently, TKA is one of the most common orthopaedic procedures
performed in the United States [1]. For many patients, pain after
TKA can be severe and can compromise postoperative management
leading to poor outcomes. Using a multimodal pain management
protocol has been shown to improve pain scores, increase patient
satisfaction, and enhance early recovery [2]. Currently, there are
many postoperative pain management protocols used by ortho-
paedic surgeons. Regional nerve blocks and local inﬁltrative anal-
gesia are two techniques that have been shown to provide
postoperative pain relief, lower narcotic usage, and improve patient
satisfaction in the early postoperative period [3]. Liposomalclosed potential or pertinent
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d/4.0/).bupivacaine, Exparel (Pacira Pharmaceuticals, Parsippany, NJ), is an
extended-release local anesthetic that uses multivesicular lipo-
somes to diffuse bupivacaine over a period of 72 hours after single
injection at the operative site [4]. Postoperative pain reduction
extended for a period of up to 72 hours would beneﬁt the patient by
allowing for a more accelerated rehabilitation protocol, which ul-
timately will lead to shorter length of hospital stay and improved
outcomes. In other surgical procedures, liposomal bupivacaine has
been shown to offer multiple clinical advantages over short-acting
bupivacaine HCl. After hemorrhoidectomy, it demonstrated a
longer duration of action, decreased opioid requirement, and fewer
opioid-related adverse effects [5]. Extended-release bupivacaine
has also been shown to provide extended pain relief and decreased
opioid use after bunionectomy compared to a placebo-controlled
group [6].
The purpose of this retrospective study was to understand the
contribution to pain control and recovery after primary TKA that
liposomal bupivacaine adds in the setting of a comprehensive pain
protocol. Narcotic usage, length of hospital stay, and walking dis-
tance were the primary outcomes investigated. In addition, we
aimed to stratify this patient cohort based on comorbidities and
body mass index (BMI) to provide insight into which patient pop-
ulations will beneﬁt most from periarticular injection (PAI) using
liposomal bupivacaine.n of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
Table 1
Equianalgesic conversion.
Drug Administration Dose
(mg)
Conversion
factor
PO morphine
equivalent dose
(mg)
Morphine PO 10 1 10
IV 10 3 30
Hydromorphone PO 10 4 40
IV 10 20 200
Hydrocodone PO 10 1 10
Oxycodone PO 10 1.5 15
Tramadol PO 10 0.25 2.5
PO, oral; IV, intravenous.
Table 3
Outcomes in all patients.
Outcome & Narcotic Usage Liposomal
bupivacaine PAI
No PAI P value
Length of stay (d) 2.94 3.26 0.092
Narcotic use 0-24 h (mg) 119.04 111.58 0.608
Narcotic use 24-48 h (mg) 114.74 132.18 0.217
Narcotic use 48-72 h (mg) 60.97 89.74 0.009
Walking distance POD 1 (ft) 61.32 44.5 0.067
Walking distance POD 2 (ft) 97.15 81.42 0.229
Walking distance POD 3 (ft) 101.93 123.07 0.246
POD, postoperative day; PAI, periarticular injection.
B.T. Webb et al. / Arthroplasty Today 1 (2015) 117e120118Material and methods
Fifty consecutive patients who underwent primary TKA and
received an intraoperative PAI using liposomal bupivacaine be-
tween April 2013 and August 2013 were retrospectively reviewed.
A separate cohort of ﬁfty consecutive patients who underwent
primary TKAwithout PAI between June 2012 and August 2012 were
retrospectively included as a control group. All procedures were
performed by a single surgeon. This study was approved by our
institutional review board and was Health Insurance Portability
and Accountability Act compliant.
All patients received a single-shot femoral and sciatic nerve
block performed by the anesthesia staff, and all patients received
intravenous sedation unless general anesthesia was required for
better airway control. A subvastus approach was the primary mode
of exposure in both groups unless there was a contraindication. All
cases were performed using a Stryker Triathlon TKA implant
(Stryker, Mahwah, NJ). In the study group, the intraoperative PAI
was performed after all components were implanted; the wound
was irrigated with a dilute Betadine (Purdue Products LT, Stanford,
CT 06901) irrigation and was thenwashed with normal saline from
a pulse irrigator. The PAI was administered according to the lipo-
somal bupivacaine manufacturer’s instructions. The PAI consisted
of 20 mL of 1.3% liposomal bupivacaine (1 vial; 266 mg) diluted
with 40-mL normal saline to create a total injection volume of 60
mL. The control group did not receive any type of intraoperative
PAI.
The postoperative pain control regimen was the same for both
groups and included the use of oral acetaminophen, celecoxib,
tramadol, patient-controlled analgesia, and oral narcotics. Patient-
controlled analgesia was administered using morphine, unless
contraindicated, at which point hydromorphone was substituted.
All postoperative pain medications administered were tabulated
and converted to a total oral morphine equivalent (mg) for use in
the comparison of the two groups (Table 1) [7].Table 2
Cohort characteristics.
Demographics Liposomal
bupivacaine PAI
No PAI Chi square df P value
Male 16 18 0.18 1 0.67
Female 34 32
P value
Age 64 (46-88) 64 (38-85) 0.837
BMI 35 (21-58) 35 (20-63) 0.93
CCI 3.34 (2-6) 3.58 (0-8) 0.366
Chi square df P value
Subvastus 33 39 1.79 1 0.18
Parapatellar 17 11
df, degrees of freedom; PAI, periarticular injection.A standardized physical therapy protocol was initiated for each
group on postoperative day 1. The physical therapy regimen con-
sisted of 2 hours of continuous passive motion machine twice daily,
assisted standing, and assisted walking. All patients were dis-
charged when deemed medically stable, their pain was under
control, and the physical therapy goals were met.
Standard statistical Student’s t tests were used to evaluate the
mean outcome of continuous variables between groups, and chi-
square tests were used to evaluate categorical variables. Dedi-
cated statistical software (SPSS 22; SPSS Inc., Chicago, IL) was used
to perform the data analysis. The two groups were compared on the
basis of length of hospital stay; amount of narcotic pain medication
used over the ﬁrst 24, 48, and 72 hours; and the distance walked on
postoperative days 1, 2, and 3. Statistically signiﬁcant difference
was considered at P  .05 between groups.Results
Fifty consecutive patients were identiﬁed in the study group,
consisting of 34 female and 16 male patients, with an average age
of 64 (range: 46-88) years and an average BMI of 35 (range: 21-58).
This was compared to the control group of 50 consecutive patients,
consisting of 32 female and 18 male patients, with an average age
of 64 (range: 38-85) years and an average BMI of 35 (range: 20-63).
The average Charlson comorbidity index (CCI) for the study group
was 3.34 (range: 2-6), and for the control group, it was 3.58
(range: 0-8). There were no statistically signiﬁcant differences
between the groups with respect to gender, age, BMI, comorbid-
ities, or surgical approach. The cohort characteristics are outlined
in Table 2.
There was a statistically signiﬁcant reduction in the amount of
narcotics used over the 48-72-hour postoperative period in the
liposomal bupivacaine group (60.97-mg oral morphine equivalent
vs 89.74 mg, P ¼ .009). There was no statistical difference between
the two groups with respect to length of hospital stay, amount of
narcotics used from 0-24 hours and 24-48 hours, or the post-
operative walking distance (Table 3).Table 4
Outcomes in patients with BMI <40, CCI 0-3.
Outcome & narcotic usage Liposomal
bupivacaine PAI
No PAI P value
Length of stay (d) 2.64 3.06 0.004
Narcotic use 0-24 h (mg) 117.61 145.53 0.298
Narcotic use 24-48 h (mg) 110.66 182.47 0.013
Narcotic use 48-72 h (mg) 49.61 112.65 0.004
Walking distance POD 1 (ft) 73.29 59.07 0.456
Walking distance POD 2 (ft) 114.77 84.82 0.193
Walking distance POD 3 (ft) 137.27 119.38 0.545
POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI,
Charlson comorbidity index.
Table 5
Outcomes in patients with BMI <40, CCI >3.
Outcome & narcotic usage Liposomal
bupivacaine PAI
No PAI P value
Length of stay (d) 3.07 3.55 0.252
Narcotic use 0-24 h (mg) 109.8 87.5 0.283
Narcotic use 24-48 h (mg) 108.93 92.23 0.228
Narcotic use 48-72 h (mg) 75.38 68.57 0.716
Walking distance POD 1 (ft) 61.43 40.95 0.08
Walking distance POD 2 (ft) 81.64 78.23 0.828
Walking distance POD 3 (ft) 82 122.1 0.176
POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI,
Charlson comorbidity index.
Table 7
Outcomes in patients with BMI >40, CCI > 3.
Outcome & narcotic usage Liposomal
bupivacaine PAI
No PAI P value
Length of stay (d) 4 3 0.391
Narcotic use 0-24 h (mg) 77.25 119.67 0.618
Narcotic use 24-48 h (mg) 67.5 154.67 0.254
Narcotic use 48-72 h (mg) 30 125 0.237
Walking distance POD 1 (ft) 24.33 3 0.472
Walking distance POD 2 (ft) 47.67 11 0.28
POD, postoperative day; PAI, periarticular injection; BMI, body mass index;
CCI, Charlson comorbidity index.
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study group with a BMI <40 and a CCI of 0-3 were found to have a
statistically signiﬁcant difference with respect to length of stay
(2.64 vs 3.06 days, P ¼ .004), narcotic use over 24-48 hours (110.66
vs 182.47 mg, P¼ .013), and narcotic use over 48-72 hours (49.61 vs
112.65 mg, P ¼ .004). There was a trend toward increased walking
distance on postoperative day 2 (114.77 vs 84.82 ft, P ¼ .193), but
this was not statistically signiﬁcant with the numbers available for
study (Table 4). All other subsets reviewed did not show any sta-
tistically signiﬁcant differences between the two groups with the
numbers available for review (Tables 5-7).
Discussion
Periarticular injections after TKA have been widely used to
alleviate postoperative pain to improve patient satisfaction and
outcomes [8,9]. Many groups have used these injections as part of
their multimodal pain control management plan after TKA. The use
of liposomal bupivacaine as a PAI is a novel technique that can
provide long-acting postoperative pain relief [10,11].
This retrospective study was undertaken to determine whether
the addition of a PAI using liposomal bupivacaine compared to no
PAI would enhance the postoperative pain relief of patients un-
dergoing TKA. Based on our study, the use of a liposomal bupiva-
caine PAI led to a decrease in narcotic use in the immediate
postoperative period in patients undergoing primary TKA. Patients
receiving liposomal bupivacaine were able to be discharged from
the hospital sooner and had a trend toward increased walking
distance earlier in their postoperative course. The greatest beneﬁt
was seen for the healthier (CCI, 3) and nonmorbidly obese pa-
tients (BMI, <40). No statistically signiﬁcant difference in length of
stay, narcotic use, or walking distance was noted when comparing
morbidly obese (BMI, >40) patients and those with multiple
comorbidities (CCI, >3). Patients most likely to beneﬁt from the
addition of a PAI using liposomal bupivacaine in this study were
those with a BMI <40 and a CCI 3.
There are limitations to this study, but despite being a retro-
spective review, this study was performed at a single institutionTable 6
Outcomes in patients with BMI >40, CCI 0-3.
Outcome & narcotic usage Liposomal
bupivacaine PAI
No PAI P value
Length of stay (d) 3 3 1
Narcotic use 0-24 h (mg) 156.5 99.63 0.106
Narcotic use 24-48 h (mg) 155.39 126.75 0.38
Narcotic use 48-72 h (mg) 80 83.43 0.867
Walking distance POD 1 (ft) 45.56 31.43 0.482
Walking distance POD 2 (ft) 94.38 109.38 0.738
Walking distance POD 3 (ft) 96.67 156.67 0.214
POD, postoperative day; PAI, periarticular injection; BMI, body mass index; CCI,
Charlson comorbidity index.using consecutive patients, without variation in surgical technique,
anesthesia, or the postoperative protocol. The study cohort and
control groups both consisted of a consecutive series of patients
that underwent primary TKA during a similar time period of the
year to best eliminate selection bias. There are several questions
that arise from the results of this study, which need further
exploration. There is an added cost to each case using liposomal
bupivacaine as a PAI. In a study by Bagsby et al [12], they
concluded that liposomal bupivacaine PAIs provided inferior pain
control compared to the less-expensive traditional PAI using short-
acting bupivacaine. However, this was also a retrospective study
with two different surgeons, and the authors acknowledge that the
results may be technique dependent. It is also important to note
that this study compared PAI using liposomal bupivacaine versus
short-acting bupivacaine, in comparison to our study, which
compared liposomal bupivacaine to no PAI in the control group. A
prospective, randomized study by Schroer et al [13] that
comparing liposomal bupivacaine to standard bupivacaine did not
show any signiﬁcant beneﬁt between the two periarticular in-
jections in patients undergoing primary TKA. Long-acting pain
relief with the use of PAIs appears to be an important part of a
multimodal pain regimen that allows for earlier discharge and
improved outcomes. There is increasing evidence that short-stay
and outpatient TKA is feasible in the near future [14]. Long-
acting pain relief through the use of PAI may allow for this to
become a possibility. We demonstrated that healthier patients and
those with a BMI <40 had a shorter hospital stay and used fewer
narcotics with the use of liposomal bupivacaine. Patients who are
morbidly obese and with multiple medical problems may have
difﬁculty in earlier return to function because of their inherent
comorbid conditions despite the use of PAIs. In addition, it is not
clear whether there are any differences in absorption and release
of these PAIs in the morbidly obese patients because of the excess
adipose tissue. Additional studies are required to demonstrate the
true beneﬁts of liposomal bupivacaine with respect to cost effec-
tiveness compared to a hospital pharmacyeprepared PAI, actual
duration of pain relief, and its role in outpatient or short-stay
hospitalization after TKA.Conclusions
Periarticular TKA injection using liposomal bupivacaine in pa-
tients with a BMI of less than 40 kg/m2 and a comorbidity index of
less than or equal to 3 leads to earlier hospital discharge and
decreased narcotic usage.References
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